Premium
Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once‐daily atorvastatin
Author(s) -
Vrijens Bernard,
Belmans Ann,
Matthys Katelijne,
Klerk Erik de,
Lesaffre Emmanuel
Publication year - 2006
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1198
Subject(s) - medicine , dosing , atorvastatin , pharmaceutical care , regimen , pharmacy , pharmacist , intervention (counseling) , randomized controlled trial , physical therapy , family medicine , nursing
Aims Correct execution of prescribed dosing regimen(s) is essential for patients to benefit from lipid lowering treatments. The objective of this study was to estimate the effect of a pharmaceutical care program on the adherence of once‐daily atorvastatin treatment in patients with elevated cholesterol levels. Methods In both linguistic regions of Belgium, two districts were randomized between usual care and a supportive intervention program. Eligible patients included hyperlipemic subjects taking atorvastatin for at least 3 months. ‘Adherence’ was defined as the proportion of days during which the electronic device record showed that the patient had taken the daily dose. ‘Persistence’ quantifies how long the treatment is executed. Results A total of 392 patients from 35 pharmacies were included in the intent‐to‐treat (ITT) analysis of the data (194 patients received intervention and 198 in the control group). The intervention resulted in a 6.5% increase in post‐baseline adherence ( p < 0.001) mainly driven by a 13% increase in persistence at 1 year ( p = 0.002). Conclusion A supportive pharmaceutical care program consisting of review by patient and pharmacist of each patient's electronically compiled dosing history, plus educational reminders, improves patient adherence to the once‐daily atorvastatin dosing regimen, mainly by extending persistence. Copyright © 2005 John Wiley & Sons, Ltd.